In Vitro & In Vivo Diagnostic Substances
| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| BlackRock, Inc. | 10.89M | $62.0M | 11.39% | +2.00M | 2026-06-30 |
| MILLENNIUM MANAGEMENT LLC | 6.62M | $37.0M | 6.93% | -48.4K | 2026-06-30 |
| Vestal Point Capital, LP | 5.74M | $32.0M | 6.00% | +4.09M | 2026-06-30 |
| STATE STREET CORP | 4.99M | $28.0M | 5.21% | +561.0K | 2026-06-30 |
| D. E. Shaw & Co., Inc. | 4.58M | $26.0M | 4.79% | +82.4K | 2026-06-30 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.08M | $23.0M | 4.27% | +156.9K | 2026-06-30 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3.08M | $17.0M | 3.22% | +497.4K | 2026-06-30 |
| AQR CAPITAL MANAGEMENT LLC | 2.77M | $15.0M | 2.89% | +854.4K | 2026-06-30 |
| MORGAN STANLEY | 2.48M | $14.0M | 2.60% | -687.6K | 2026-06-30 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.42M | $13.0M | 2.53% | +96.8K | 2026-06-30 |
